Financial Data and Key Metrics Changes - Revenue for Q1 2022 grew 4.7% on a reported basis and 6.8% at constant currency, with a $23 million beat above the midpoint of guidance driven by strong operational performance across all segments [21][34] - Adjusted EBITDA grew 9.1%, reflecting revenue growth and ongoing productivity initiatives, while adjusted diluted EPS of $2.47 grew 13.3% [23][37] - COVID-related revenues were approximately $375 million, down about 35% compared to Q1 2021, with core businesses growing about 13% at constant currency on an organic basis [34][35] Business Line Data and Key Metrics Changes - Technology and Analytic Solutions revenue was $1,439 million, up 6.8% reported and 9.8% at constant currency, with organic growth at constant currency exceeding 10% [35] - R&D Solutions revenue was $1,934 million, up 3.5% at actual FX rates and 4.7% at constant currency, with organic growth at constant currency around 17% [35] - Contract Sales and Medical Solutions revenue was $195 million, growing 1% reported and 5.7% at constant currency, with mid-single digits organic growth at constant currency [36] Market Data and Key Metrics Changes - The company reported a record contracted backlog in R&D Solutions of $25.3 billion, growing 9.1% year-over-year, with next 12 months revenue from backlog increasing to over $7 billion, growing 8% from a year ago [32][38] - Clinical trials started up 7% in Q1 compared to last year, with a 14% increase in oncology trial starts, indicating strong market demand [17] Company Strategy and Development Direction - The company is focusing on leveraging its connected intelligence framework to support the emerging needs of the pharma industry, including a multiyear agreement with Argenx for rare disease product development [24][25] - The company aims to maintain a low leverage ratio while pursuing aggressive share repurchases, with over $403 million repurchased in Q1 [40][66] - The company is cautious about M&A activities, looking for strategic acquisitions that add capabilities or allow entry into adjacent markets, while being selective due to high valuations [83][86] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the underlying business despite macroeconomic challenges, maintaining full-year 2022 profit guidance [46][41] - The company anticipates a revenue disruption from the Russia-Ukraine crisis estimated at $40 million to $50 million, primarily front-loaded in the year [41][51] - Management noted that the labor market remains competitive, but they are actively recruiting and managing attrition effectively [70][72] Other Important Information - The company was named the top CRO in overall reputation by clinical trial sites globally, reflecting strong performance in decentralized trials and patient recruitment [33] - The company has established a free online service for medical professionals to assist with the refugee crisis resulting from the Ukraine conflict [10] Q&A Session Summary Question: Impact of Russia-Ukraine on Q1 and annual projections - Management indicated that the impact in Q1 was minimal, with a projected annual impact of $40 million to $50 million, likely front-loaded in the year [50][51] Question: Revenue and profitability pacing - Management confirmed that the underlying business is consistent and strong, with expected organic growth rates in line with guidance [60][62] Question: Labor trends and management - Management acknowledged competitive labor trends but noted effective recruitment strategies and increased employee satisfaction due to high bonus payouts [70][74] Question: Real world evidence business growth - Management reported strong growth in the real world evidence segment, expecting continued double-digit growth despite the decline in COVID-related work [78][79] Question: M&A strategy and market conditions - Management remains cautious about M&A, focusing on strategic acquisitions that are accretive and necessary, while being selective due to high valuations [83][86]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Delaware 27-1341991 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 I ...

| --- | --- | |-----------------------|-------| | | | | | | | | | | Q4 2021 Earnings Call | | | February 15, 2022 | | IQVIA Template (V2.1.0) Legal IQVIA Template (V2.1.0) 1 This presentation should be viewed in conjunction with IQVIA's Q4 2021 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Secur ...

Financial Data and Key Metrics Changes - Revenue for Q4 2021 grew 10.2% on a reported basis and 11.6% at constant currency, reaching $3.636 billion, with a $62 million beat above the midpoint of guidance [13][29] - Adjusted EBITDA for Q4 was $828 million, reflecting a 12.7% growth, while full-year adjusted EBITDA was $3.022 billion, up 26.8% year-over-year [36][39] - Adjusted diluted EPS for Q4 was $2.55, growing 20.9%, with full-year adjusted net income at $1.760 billion or $9.03 per share, up 41% [37][39] Business Line Data and Key Metrics Changes - Technology & Analytics Solutions (TAS) revenue for Q4 was $1.496 billion, up 5% reported and 6.6% at constant currency, with organic growth at high single digits excluding COVID-related work [31] - R&D Solutions revenue for Q4 was $1.944 billion, up 15.4% at actual FX rates and 16.3% at constant currency, with organic growth at approximately 25% excluding COVID-related work [32] - Contract Sales & Medical Solutions (CSMS) revenue for Q4 was $196 million, growing 3.7% reported and 7.4% at constant currency, with low single digits organic growth excluding COVID-related work [32] Market Data and Key Metrics Changes - COVID-related revenues in Q4 were approximately $325 million, down about 25% versus Q4 2020, with organic growth in the base business at mid-teens at constant currency [30] - For the full year, COVID-related revenues were approximately $1.8 billion, accounting for about half of the growth in 2021 [33] Company Strategy and Development Direction - The company aims to achieve at least $20 billion in revenue by 2025 as part of its new 20 x 2025 strategy, with a focus on refining strategies and action plans for growth [10][11] - The company has been recognized on Fortune's list of the World's Most Admired Companies, ranking first in several categories, highlighting its leadership position in the market [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2022 guidance despite challenges from COVID-19 and foreign exchange headwinds, anticipating strong growth in the base business [12][43] - The company is addressing labor and wage inflation challenges by implementing flexible work arrangements and compensation programs, while also benefiting from cost improvement initiatives [60][61] Other Important Information - The company reported a record free cash flow of $2.3 billion for the full year, allowing for significant capital deployment in investments, acquisitions, and share repurchases [39][41] - The Board approved a $2 billion increase to the share repurchase authorization, bringing the total to over $2.5 billion [42] Q&A Session Summary Question: Discussion on COVID-related work and its duration - Management indicated that COVID-related work will gradually decline over the next two years, with some residual work expected to continue into 2023 [57][59] Question: Insights on labor and wage inflation - Management acknowledged that labor management is a significant operational challenge, but they are implementing various strategies to mitigate wage inflation impacts while maintaining margin growth [60][61] Question: Impact of biotech funding environment - Management reported no significant changes in the RFP pipeline, with strong demand continuing in the R&D segment, despite some fluctuations in biotech funding [66][72] Question: Breakdown of revenue growth in TAS - Management detailed that TAS growth is driven by three tiers: core information solutions (flattish growth), analytics and consulting (moderate growth), and higher growth from real-world evidence and technology [110][115]

Q3 2021 Financial Performance - Revenue increased to $3391 million, a 217% increase AFx compared to $2786 million in Q3 2020[8,9] - Adjusted EBITDA reached $728 million, up from $604 million in Q3 2020[8,12] - Adjusted Diluted EPS rose to $217, compared to $163 in Q3 2020[8,12] Year-to-Date Performance - Year-to-date revenue reached $10238 million, a 270% increase AFx compared to $8061 million in 2020[9] - Year-to-date Adjusted EBITDA was $2194 million, compared to $1649 million in 2020[12] - Year-to-date Adjusted Diluted EPS was $648, compared to $432 in 2020[12] Segment Revenue Growth - Technology & Analytics Solutions revenue was $1337 million, a 108% increase AFx compared to $1207 million in Q3 2020[9] - Research & Development Solutions revenue was $1853 million, a 324% increase AFx compared to $1400 million in Q3 2020[9] - Contract Sales & Medical Solutions revenue was $201 million, a 123% increase AFx compared to $179 million in Q3 2020[9] Backlog and Bookings - Research & Development Solutions backlog increased by 127% to $244 billion[14] - Last Twelve Months Net New Bookings increased by 173% to $101 billion[14] Full Year 2021 Guidance - Updated revenue guidance is $13775 - $13850 million, representing a 213% - 219% increase[18] - Updated Adjusted EBITDA guidance is $2980 - $3010 million, representing a 250% - 263% increase[18] - Updated Adjusted Diluted EPS guidance is $885 - $895, representing a 379% - 394% increase[18]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 ...

Financial Data and Key Metrics Changes - Revenue for Q3 2021 was $3.391 billion, growing 21.7% on a reported basis and 21.1% at constant currency, with year-to-date revenue at $10.238 billion, growing 27% reported and 25% at constant currency [31][14] - Adjusted EBITDA for Q3 was $728 million, up 20.5%, with year-to-date adjusted EBITDA at $2.194 billion, growing 33.1% year-over-year [34] - Adjusted diluted EPS for Q3 was $2.17, growing 33.1%, with year-to-date adjusted net income at $1.264 billion or $6.48 per share [34][15] - The company raised its full-year 2021 revenue guidance by $188 million, now expecting revenue between $13.775 billion and $13.850 billion, representing year-over-year growth of 21.3% to 21.9% [38] Business Line Data and Key Metrics Changes - Technology & Analytics Solutions revenue for Q3 was $1.337 billion, up 10.8% reported and 9.9% at constant currency, with year-to-date revenue at $4.38 billion, up 17.6% reported and 14.9% at constant currency [31] - R&D Solutions revenue for Q3 was $1.853 billion, up 32.4% at actual FX rates and 31.9% at constant currency, with year-to-date revenue at $5.612 billion, up 37.7% reported and 36.2% at constant currency [32] - Contract sales in Medical Solutions revenue for Q3 was $201 million, up 12.3% reported and 12.8% at constant currency, with year-to-date revenue at $588 million, growing 6.5% reported and 5.1% at constant currency [33] Market Data and Key Metrics Changes - The pipeline of late-stage molecules is at an all-time high with almost 3,000 molecules in active Phase II or Phase III development [12] - Clinical trial starts are trending well ahead of recent years, with year-to-date starts up 23% over 2020 and 13% over 2019 [12] - New drug approvals by the FDA are keeping pace with historically high levels, with 40 new drugs approved year-to-date [12] Company Strategy and Development Direction - The company is focusing on expanding its lab capabilities, recently opening a new 160,000 square foot innovation laboratory in North Carolina [27] - The company is investing in decentralized trials (DCT) and has developed innovative clinical patient engagement offerings to improve recruitment and diversity in clinical trials [21][24] - The company plans to provide financial guidance for 2022 at the upcoming analyst and investor conference on November 16 [13] Management's Comments on Operating Environment and Future Outlook - Management remains bullish on the outlook for end markets and the company, citing strong dynamics in the life sciences industry [12] - The company has learned to manage disruptions caused by COVID-19, and the operational impact has been minimal [10] - Management acknowledged challenges in the labor market but noted that margin expansion has continued despite cost pressures [50] Other Important Information - The company reported a net leverage ratio of 3.65x trailing 12-month adjusted EBITDA as of September 30 [36] - Free cash flow for the year-to-date was almost $1.8 billion, showing a strong improvement trend over the past three years [37] Q&A Session Summary Question: Operational implications of DCT and OCT offerings - Management noted that DCT increases productivity and reduces labor, enabling more efficient execution of trials [47] Question: Impact of labor market on EBITDA margins - Management confirmed that the tight labor market is a headwind for margins, but productivity measures have helped offset this [50] Question: M&A spend in the quarter - Management indicated that M&A contributions were minimal in Q3, with a larger impact expected in Q4 [54] Question: COVID contributions to revenue and bookings - Management stated that COVID-related work is expected to taper off gradually, with a strong underlying business in other therapeutic areas [68] Question: Market share trends in R&DS - Management expressed confidence in gaining market share due to disruptions among competitors and a strong biotech environment [105]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-35907 ____ ...

| --- | --- | |-----------------------|-------| | | | | | | | | | | Q2 2021 Earnings Call | | | July 27, 2021 | | IQVIA Template (V2.1.0) Legal IQVIA Template (V2.1.0) 1 This presentation should be viewed in conjunction with IQVIA's Q2 2021 earnings call Safe Harbor Statement for Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securitie ...

IQVIA Holdings, Inc. (NYSE:IQV) Q2 2021 Earnings Conference Call July 27, 2021 9:00 AM ET Company Participants Nicholas Childs - SVP, Financial Planning & Analysis Ari Bousbib - Chairman, President & CEO Ronald Bruehlman - EVP & CFO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Shlomo Rosenbaum - Stifel, Nicolaus & Company John Kreger - William Blair & Company Tycho Peterson - JPMorgan Chase & Co. Jack Meehan - Nephron Research Daniel Leonard - Wells Fargo Securities Patrick Donnelly - ...